Meta-analysis-based cost-effectiveness evaluation of Xihuang pill in combination with chemotherapy for breast cancer
Objective To evaluate the efficacy and cost of Xihuang pill combined with chemotherapy in the treatment of breast cancer by cost-effectiveness analysis based on the meta-analysis,and to provide reference for clinical optimization of health resource allocation.Methods Xihuang Pill and chemotherapy were the treatment group,and conventional chemotherapy were the control group.According to the Cocharane system evaluation,RevMan5.4 software was used to conduct meta-analysis and count the costs of two groups.Cost-effectiveness and sensitivity analysis were performed by comparing the differences in efficacy and costs.Results A total of 7 randomized controlled trials were included in the article.According to the results of meta-analysis,the difference in the effective rate of Xihuang pill combined with chemotherapy compared with the control group was statistically significant(P＜0.05),and the clinical effective rate and safety were higher and the recurrence rate was lower compared with the control group.Meanwhile,the results of cost-effectiveness analysis showed that the cost-effectiveness ratio of Xihuang pill combined with cyclophosphamide+Doxorubicin hydrochloride(Adriamycin)+fluorouracil(CAF)regimen was ¥101.07,and the cost-effectiveness ratio of Xihuang pill combined with cyclophosphamide+Epirubicin+fluorouracil(CEF)regimen was ¥64.54,both of which was lower than that of the control group.And the incremental cost effectiveness ratio values of the two scenarios were ¥59.97 and ¥48.13,respectively,which indicated that the Xihuang pill combined with CAF and CEF regimen had a greater cost-effectiveness advantage.The cost-effectiveness of Xihuang pill combined with other programs was not obvious.Conclusion Xihuang pill combined with CAF and CEF regimen is more economical in the treatment of breast cancer,and is the preferred treatment scheme.
breast cancerXihuang pillcost effectiveness analysissystem evaluationmeta-analysis
万方数据
维普
